-+ 0.00%
-+ 0.00%
-+ 0.00%

UBS Initiates Coverage On Evommune with Neutral Rating, Announces Price Target of $8

Benzinga·10/12/2026 13:31:06
UBS analyst Alice Nettleton initiates coverage on Evommune (NYSE:EVMN) with a Neutral rating and announces Price Target of $8.